Literature DB >> 15496304

The neuronal selective nitric oxide synthase inhibitor, Nomega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice.

Daniel Klamer1, Jörgen A Engel, Lennart Svensson.   

Abstract

Phencyclidine has frequently been used to model schizophrenia in animals. In the present study, the ability of the neuronal selective nitric oxide synthase (NOS) inhibitor, Nomega-propyl-L-arginine, to block the behavioural effects of phencyclidine in mice was investigated. N(omega)-propyl-L-arginine (20 mg/kg) was found to block both phencyclidine (4 mg/kg)-induced disruption of prepulse inhibition and phencyclidine-induced stimulation of locomotor activity in the mice tested. It is concluded that the NOS-sensitive behavioural effects of phencyclidine in rodents is dependent on neuronal NOS and that NO may play a role in the psychotomimetic effects of phencyclidine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496304     DOI: 10.1016/j.ejphar.2004.09.042

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Effects of blockade of glutamate NMDA receptors or of NO synthase on the development or the expression of associative or non-associative sensitization to locomotor activation by morphine.

Authors:  A Atalla; K Kuschinsky
Journal:  J Neural Transm (Vienna)       Date:  2005-04-22       Impact factor: 3.575

2.  Activation of a nitric-oxide-sensitive cAMP pathway with phencyclidine: elevated hippocampal cAMP levels are temporally associated with deficits in prepulse inhibition.

Authors:  Daniel Klamer; Erik Pålsson; Kim Fejgin; Jianhua Zhang; Jörgen A Engel; Lennart Svensson
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

3.  Differential central NOS-NO signaling underlies clonidine exacerbation of ethanol-evoked behavioral impairment.

Authors:  Tara S Bender; Abdel A Abdel-Rahman
Journal:  Alcohol Clin Exp Res       Date:  2009-12-17       Impact factor: 3.455

4.  Information processing deficits and nitric oxide signalling in the phencyclidine model of schizophrenia.

Authors:  Erik Pålsson; John Lowry; Daniel Klamer
Journal:  Psychopharmacology (Berl)       Date:  2010-08-28       Impact factor: 4.530

5.  A NOS1 variant implicated in cognitive performance influences evoked neural responses during a high density EEG study of early visual perception.

Authors:  Therese O'Donoghue; Derek W Morris; Ciara Fahey; Andreia Da Costa; John J Foxe; Doreen Hoerold; Daniela Tropea; Michael Gill; Aiden Corvin; Gary Donohoe
Journal:  Hum Brain Mapp       Date:  2011-04-21       Impact factor: 5.038

6.  Effects of the nitric oxide synthase inhibitor L-NAME on recognition and spatial memory deficits produced by different NMDA receptor antagonists in the rat.

Authors:  Antonios Boultadakis; Nikolaos Pitsikas
Journal:  Neuropsychopharmacology       Date:  2010-07-21       Impact factor: 7.853

Review 7.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

8.  Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice.

Authors:  Ana C Issy; João Francisco C Pedrazzi; Bruno H Yoneyama; Elaine A Del-Bel
Journal:  Psychopharmacology (Berl)       Date:  2013-10-08       Impact factor: 4.530

9.  Evidence for involvement of nitric oxide and GABA(B) receptors in MK-801- stimulated release of glutamate in rat prefrontal cortex.

Authors:  Nicole L Roenker; Gary A Gudelsky; Rebecca Ahlbrand; Paul S Horn; Neil M Richtand
Journal:  Neuropharmacology       Date:  2012-05-09       Impact factor: 5.250

Review 10.  Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges.

Authors:  Jan Víteček; Antonín Lojek; Giuseppe Valacchi; Lukáš Kubala
Journal:  Mediators Inflamm       Date:  2012-09-04       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.